Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Prostate-specific antigen screening: pro.

Loeb S, Catalona WJ.

Curr Opin Urol. 2010 May;20(3):185-8. doi: 10.1097/MOU.0b013e3283384047. Review.

PMID:
20224413
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

Vutuc C, Schernhammer ES, Haidinger G, Waldhör T.

Wien Klin Wochenschr. 2005 Jul;117(13-14):457-61.

PMID:
16091872
[PubMed - indexed for MEDLINE]
3.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

PMID:
22228146
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
[PubMed - indexed for MEDLINE]
5.

PSA-based screening for prostate cancer. Too many adverse effects.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):215-7. Review.

PMID:
23016259
[PubMed - indexed for MEDLINE]
6.

[Advancements in PSA-based screening for prostate cancer].

Ito K.

Rinsho Byori. 2004 Jul;52(7):611-7. Review. Japanese.

PMID:
15344561
[PubMed - indexed for MEDLINE]
7.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
[PubMed - indexed for MEDLINE]
8.
9.

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.

Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G.

BJU Int. 2000 Jun;85(9):1078-84.

PMID:
10848699
[PubMed - indexed for MEDLINE]
10.

Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.

Payne H, Cornford P.

Urol Oncol. 2011 Nov-Dec;29(6):593-601. doi: 10.1016/j.urolonc.2009.11.003. Epub 2010 Jan 8. Review.

PMID:
20060331
[PubMed - indexed for MEDLINE]
11.

Prostate-specific antigen in clinical practice.

Loeb S, Catalona WJ.

Cancer Lett. 2007 Apr 28;249(1):30-9. Epub 2007 Jan 26. Review.

PMID:
17258389
[PubMed - indexed for MEDLINE]
12.

Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.

Whittemore AS, Cirillo PM, Feldman D, Cohn BA.

J Urol. 2005 Sep;174(3):872-6; discussion 876.

PMID:
16093978
[PubMed - indexed for MEDLINE]
13.

Prognostic value of serum markers for prostate cancer.

Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.

Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. Review.

PMID:
16019759
[PubMed - indexed for MEDLINE]
14.

Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.

Larsen SB, Brasso K, Iversen P, Christensen J, Christiansen M, Carlsson S, Lilja H, Friis S, Tjønneland A, Dalton SO.

Eur J Cancer. 2013 Sep;49(14):3041-8. doi: 10.1016/j.ejca.2013.04.015. Epub 2013 May 17.

PMID:
23684783
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

PMID:
24682399
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.

PMID:
22704366
[PubMed - indexed for MEDLINE]
17.

Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

Duffy MJ.

Ann Clin Biochem. 2011 Jul;48(Pt 4):310-6. doi: 10.1258/acb.2011.010273. Epub 2011 Apr 27. Review.

PMID:
21525152
[PubMed - indexed for MEDLINE]
18.

Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.

Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.

Cancer. 2005 Jan 15;103(2):242-50.

PMID:
15578715
[PubMed - indexed for MEDLINE]
Free Article
19.

Baseline prostate-specific antigen testing at a young age.

Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH.

Eur Urol. 2012 Jan;61(1):1-7. doi: 10.1016/j.eururo.2011.07.067. Epub 2011 Aug 10. Review.

PMID:
21862205
[PubMed - indexed for MEDLINE]
20.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

PMID:
23924423
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk